Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 453 people in the pemetrexed plus carboplatin group and 455 people in the etoposide plus carboplatin group — a total of 908 participants. The trial was comparing two different chemotherapy combinations in people with a type of lung cancer called small cell lung cancer. The main thing the trial was measuring was how long participants lived overall (called "overall survival"). It also measured how long it took before the cancer showed signs of growing again, and how participants rated their own quality of life using a standard questionnaire. The reported data shows that, on average, participants in the pemetrexed plus carboplatin group lived for 8.1 months from the time they enrolled, while those in the etoposide plus carboplatin group lived for 10.6 months. When looking at how long it was before the cancer appeared to progress, the reported figures were 3.8 months for the pemetrexed plus carboplatin group and 5.4 months for the etoposide plus carboplatin group. For quality of life, both groups started with similar scores on the questionnaire (around 87–88 out of a possible 136, where higher means better). The reported changes from that starting score across treatment cycles were small in both groups — generally less than 2 points in either direction — which is below the 5-point threshold the researchers described as a meaningful difference. The reported data also includes results broken down by subgroups such as sex, age, and other baseline characteristics, with overall survival figures varying across these subgroups. For two particular subgroups, the statistical analysis could not be fully completed for the etoposide plus carboplatin group, so only participant numbers were reported for those. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lung Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with small cell lung cancer (SCLC) that has spread widely in the body (called "extensive stage")
- You are able to take care of yourself day-to-day, even if you are unable to do regular work activities
- You have not yet received any cancer treatments for your small cell lung cancer
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously taken part in a clinical study that involved a drug called pemetrexed
- You have received a drug in the last 30 days that has not yet been officially approved for use by health regulators for any medical condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 15 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Overall Survival
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.